2013
DOI: 10.1093/ije/dyt018
|View full text |Cite
|
Sign up to set email alerts
|

Cohort Profile: The Berlin Aging Study II (BASE-II)†

Abstract: Similar to other industrialized countries, Germany's population is ageing. Whereas some people enjoy good physical and cognitive health into old age, others suffer from a multitude of age-related disorders and impairments which reduce life expectancy and affect quality of life. To identify and characterize the factors associated with 'healthy' vs. 'unhealthy' ageing, we have launched the Berlin Aging Study II (BASE-II), a multidisciplinary and multi-institutional project that ascertains a large number of agein… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
259
0
3

Year Published

2013
2013
2024
2024

Publication Types

Select...
9

Relationship

4
5

Authors

Journals

citations
Cited by 245 publications
(270 citation statements)
references
References 15 publications
1
259
0
3
Order By: Relevance
“…The advances began with the identification of the BCR-ABL1 gene in chronic myeloid leukemia (CML) in 1985, leading to the introduction of ABL1 tyrosine kinase inhibitors (TKIs), and the JAK2 V617F mutation in polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) in 2005, leading to the JAK inhibitors. [1][2][3] CML is now arguably the most successfully treated human malignancy. Despite these remarkable achievements, the quest for cure, functionally defined as treatment-free remission after discontinuation of TKI therapy, remains difficult.…”
Section: T-cell Immunosenescencementioning
confidence: 99%
“…The advances began with the identification of the BCR-ABL1 gene in chronic myeloid leukemia (CML) in 1985, leading to the introduction of ABL1 tyrosine kinase inhibitors (TKIs), and the JAK2 V617F mutation in polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) in 2005, leading to the JAK inhibitors. [1][2][3] CML is now arguably the most successfully treated human malignancy. Despite these remarkable achievements, the quest for cure, functionally defined as treatment-free remission after discontinuation of TKI therapy, remains difficult.…”
Section: T-cell Immunosenescencementioning
confidence: 99%
“…Detailed descriptions of participants, variables, and procedures can be found in previous publications (for the BASE, see Baltes & Mayer, 1999; for the BASE-II, see Bertram et al, 2014). Select details relevant to this report are given below.…”
Section: Methodsmentioning
confidence: 99%
“…Aging Study II (BASE-II), a survey that primarily focuses on multidimensional processes of physical and mental aging (see Bertram et al 2014). The analysis reveals a high impact of cognitive functioning at the various stages of the survey response process.…”
Section: The Analysis Builds On a Randomized Mode Experiments Implemenmentioning
confidence: 99%
“…This longitudinal survey focuses primarily on multidimensional processes of physical and mental aging (see Bertram et al 2014). The BASE-II sample is a non-probability sample consisting of 1600 elderly (age 60 to 80) and a reference group of 600 younger residents (age 20 to 35) living in greater Berlin.…”
Section: Datamentioning
confidence: 99%